Denali Therapeutics (DNLI) Assets Average (2018 - 2026)

Denali Therapeutics (DNLI) has 9 years of Assets Average data on file, last reported at $1.2 billion in Q1 2026.

• Quarterly Assets Average fell 8.87% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 8.87% YoY) and the FY2025 annual result came in at $1.3 billion, changed 0.36% from the prior year.
• Assets Average rose to $1.2 billion in Q1 2026 per DNLI's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.5 billion in Q2 2024 and bottomed at $1.1 billion in Q4 2025.
• The 5-year median for Assets Average is $1.3 billion (2025), against an average of $1.3 billion.
• The widest annual swing landed in 2024, when Assets Average rose 18.3%; it then retreated 24.85% in 2025.
• Tracing DNLI's Assets Average over 5 years: stood at $1.3 billion in 2022, then declined by 11.06% to $1.2 billion in 2023, then climbed by 18.3% to $1.4 billion in 2024, then decreased by 22.2% to $1.1 billion in 2025, then advanced by 9.56% to $1.2 billion in 2026.
• Per Business Quant, the three latest DNLI Assets Average figures stand at $1.2 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025).

Peer Comparison